The aged extracellular matrix accumulates collagen fragments that engage α(v)β(3)‑integrin, suppressing HAS2 transcription via ROCK/ERK inhibition [1]. Parallelly, miR‑23a‑3p is up‑regulated in senescent fibroblasts and directly targets HAS2 mRNA [2]. We hypothesize that these two repression mechanisms converge on a common epigenetic‑post‑transcriptional silencing hub at the HAS2 locus, creating a synergistic block that is greater than the sum of its parts. Specifically, α(v)β(3)‑integrin activation triggers FAK/Src signaling, which recruits the DNA methyltransferase DNMT3A to the HAS2 promoter, establishing CpG methylation that reduces basal transcription. Simultaneously, miR‑23a‑3p bound to the HAS2 3′‑UTR recruits the CCR4‑NOT deadenylase complex, accelerating mRNA decay. The methylated promoter renders the transcript more susceptible to miR‑23a‑3p‑mediated destabilization, producing a feed‑forward loop that sharply lowers HAS2 output and HA synthesis.

As HA synthesis falls, the existing high‑molecular‑weight HA is cleaved by ROS‑activated hyaluronidases into a spectrum of fragments. We propose that fragments in the 5‑8 kDa range act as a molecular rheostat: they possess sufficient affinity for CD44 to partially occupy the receptor, yet retain exposed glucuronic acid motifs that enable TLR4/MD‑2 binding. At this size, CD44 occupancy is sub‑optimal, weakening its inhibitory brake on TLR2/4 signaling [6], while TLR4‑MyD88‑NF‑κB activation is sufficiently triggered to drive pro‑inflammatory cytokine production [5]. Below ~5 kDa, fragments fail to engage CD44 effectively, and above ~8 kDa steric hindrance prevents TLR4 access, preserving anti‑inflammatory signaling.

Thus, the hypothesis makes three testable predictions: (1) Simultaneous inhibition of α(v)β(3)‑integrin (e.g., with cilengitide) and miR‑23a‑3p (with a locked‑nucleic‑acid antagomir) in aged human dermal fibroblasts will restore HAS2 mRNA and protein levels to >80 % of young‑cell baseline, whereas each single treatment will yield <40 % recovery, demonstrating synergism. (2) Restored HAS2 expression will shift the secreted HA size distribution toward >500 kDa, reducing the proportion of 5‑8 kDa fragments by >60 % as measured by SEC‑MALS. (3) Conditioned media from fibroblasts treated with the dual repression rescue will suppress NF‑κB luciferase reporter activation in macrophages stimulated with LPS/TLR2 ligands by >50 % compared with media from untreated aged fibroblasts, an effect abolished by adding exogenous 6‑kDa HA fragments.

Falsifiability: If dual targeting fails to produce a synergistic increase in HAS2 expression, or if HA size shift does not correlate with altered macrophage NF‑κB activity, the proposed mechanistic link between integrin‑DNMT3A/miR‑23a‑3p cooperation and the HA fragment size‑switch would be refuted. These experiments employ readily available pharmacological and nucleic‑acid tools, quantitative PCR, Western blot, HA sizing, and reporter assays, providing a clear, falsifiable path forward.